Ancel, Julien
Belgacemi, Randa
Perotin, Jeanne-Marie
Diabasana, Zania
Dury, Sandra
Dewolf, Maxime
Bonnomet, Arnaud
Lalun, Nathalie
Birembaut, Philippe
Polette, Myriam
Deslée, Gaëtan
Dormoy, Valérian http://orcid.org/0000-0003-1725-371X
Funding for this research was provided by:
Institut National de la Santé et de la Recherche Médicale
Université de Reims Champagne-Ardenne
Article History
Received: 21 January 2020
Accepted: 2 August 2020
First Online: 7 August 2020
Ethics approval and consent to participate
: Non-COPD and COPD patients were recruited from the Department of pulmonary medicine at University Hospital of Reims (France) and included in the Research and Innovation in Chronic Inflammatory Respiratory Diseases (RINNOPARI, NCT02924818) cohort. The study was approved by the ethics committee (CCP Dijon EST I, N°2016-A00242–49) and was conducted in accordance with the ethical guidelines of the Declaration of Helsinki.
: All subjects gave their written informed consent prior to inclusion in the study.
: Dr. Deslée reports personal fees from Nuvaira, personal fees from BTG/PneumRx, personal fees from Chiesi, personal fees from Boehringer, personal fees from Astra Zeneca, outside the submitted work. Dr. Dury reports personal fees from Novartis, personal fees from Boehringer-Ingelheim, personal fees from Chiesi, personal fees from Roche, outside the submitted work. Dr. Dormoy reports personal fees from Chiesi outside the submitted work.